Ursula A. Matulonis, MD, on KEYNOTE-100 Study Highlights for Patients

Video

The expert from Dana-Farber Cancer Institute spoke about the study of pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.

In an interview with CancerNetwork®, Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, explained the key highlights that patients with cancer should be aware of regarding the KEYNOTE-100 trial.

Final results from the KEYNOTE-100 trial of pembrolizumab (Keytruda) in patients with advanced recurrent ovarian cancer suggested that pembrolizumab monotherapy was associated with modest antitumor activity in patients with recurrent advanced ovarian cancer.

In addition, the study, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, did not report any new safety signals.

Transcription:

So single… so using pembrolizumab as a single agent has modest activity, meaning it's around 8%. So, 8 out of 100 women with recurrent ovarian cancer will have a significant response to this drug. Now it sounds low. But unfortunately, for women who have recurrent ovarian cancer, the single agent response rates of non-platinum-based chemotherapy are pretty comparable. In some instances, they're actually zero percent. So, 8% doesn't sound high, and it's not, but it is seemingly comparable to chemotherapy in this single arm trial. So, this was not a randomized study, where we randomized pembrolizumab to chemotherapy, but this was a single arm trial.

Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Related Content